See Section 6.2 for the evaluation of measurable disease. Patients with surgically resected metastatic disease at high risk of relapse are also eligible. 2.1.1.3 Prior therapy: Patient s must have completed or had disease progression on at least one prior line of disease- appropriate therapy for metastatic disease, or not be candidates for therapy of proven efficacy for their disease. 2.1.1.4 There should be a minimum of 4 weeks from any prior chemotherapy, immunotherapy and/or radiation, with the exception of hormonal therapy for prostate and breast 28 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential cancers , HER2-directed therapy for H ER2+ breast cancer (3+ IHC or FISH+), and erlotinib in EGFR -mutated lung cancer in the expansion cohort as det ailed in section . There should be a minimum of 6 weeks from any prior antibody therapies, (such as ipilimumab or anti-PD1/PDL1) due to prolonged half- life. 2.1.1.5 Patient s must have r ecovered ( grade 1 or baseline) from any clinically significant toxicity associated with prior therapy. Typically , this is 3 –4 weeks for patients who most recently received cytotoxic therapy, except for the nitrosoureas and mitomycin C, for which 6 weeks is needed for recovery. 2.1.1.6 Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of MVA-b rachyury -TRICOM vaccine in patients < 18 years of age, children are excluded from this study but will be eligible for future pediatric trials. 2.1.1.7 ECOG performance status ≤ 1 (Karnofsky ≥ 70%, see Appendix A , Sectio n 13.1).